 Endometrial Neoplasms
"Endometrial Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Descriptor ID |
D016889
|
| MeSH Number(s) |
C04.588.945.418.948.585 C13.351.500.852.762.200 C13.351.937.418.875.200
|
| Concept/Terms |
Endometrial Neoplasms- Endometrial Neoplasms
- Endometrial Neoplasm
- Neoplasm, Endometrial
- Neoplasms, Endometrial
Endometrial Carcinoma- Endometrial Carcinoma
- Carcinoma, Endometrial
- Carcinomas, Endometrial
- Endometrial Carcinomas
- Endometrial Cancer
- Cancer, Endometrial
- Cancers, Endometrial
- Endometrial Cancers
- Endometrium Cancer
- Cancer, Endometrium
- Cancers, Endometrium
- Cancer of the Endometrium
- Carcinoma of Endometrium
- Endometrium Carcinoma
- Endometrium Carcinomas
- Cancer of Endometrium
- Endometrium Cancers
|
Below are MeSH descriptors whose meaning is more general than "Endometrial Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Endometrial Neoplasms".
This graph shows the total number of publications written about "Endometrial Neoplasms" by people in this website by year, and whether "Endometrial Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 1998 | 3 | 0 | 3 | | 1999 | 1 | 0 | 1 | | 2002 | 2 | 0 | 2 | | 2004 | 1 | 1 | 2 | | 2005 | 3 | 0 | 3 | | 2006 | 4 | 1 | 5 | | 2007 | 2 | 0 | 2 | | 2008 | 3 | 0 | 3 | | 2009 | 5 | 0 | 5 | | 2010 | 3 | 0 | 3 | | 2011 | 5 | 1 | 6 | | 2012 | 2 | 0 | 2 | | 2013 | 6 | 1 | 7 | | 2014 | 6 | 0 | 6 | | 2015 | 6 | 1 | 7 | | 2016 | 4 | 0 | 4 | | 2017 | 8 | 1 | 9 | | 2018 | 3 | 0 | 3 | | 2019 | 9 | 0 | 9 | | 2020 | 6 | 0 | 6 | | 2021 | 4 | 0 | 4 | | 2022 | 5 | 0 | 5 | | 2023 | 12 | 0 | 12 | | 2024 | 9 | 0 | 9 | | 2025 | 15 | 1 | 16 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Endometrial Neoplasms" by people in Profiles.
-
Rabban JT, Wolsky RJ, Kayraklioglu N, Davies KD, Aisner DL, Devine WP. Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification. Mod Pathol. 2026 Jun; 39(6):101005.
-
Walia S, Jain E, Kandukuri SR, Bakkar R, Gong Y, Costigan D, Lobo A, Balzer B, Gasper C, Biswal R, Cima L, Dixit M, Arora S, Malik V, Hirsch MS, Lali BS, Singh C, Samrao D, Jain D, Dhall D, Midha D, Mukherjee G, Gulati H, Singh H, Varshney J, Zameer L, Kahar M, Swain M, Gupta N, Gupta P, Moatamed NA, Kumari N, Afroz N, Manzoor Ali NK, Elhence PA, Diwaker P, Sardana R, Ojha S, Mathur SR, Menon S, Satish Rao I, Shinde S, Sharma S, Naik S, Kodandapani S, Salibay CJ, Nagos V, Lastra RR, Sangoi A, Li Z, Fadare O, McCluggage WG, Carlson J, Rabban J, Mohanty SK. Utilization of Key Morphologic and Molecular Prognostic and Predictive Parameters in Endometrial Malignancies: A Survey of Gynecologic Pathologists. Int J Surg Pathol. 2026 Aug; 34(5):1134-1145.
-
Willman G, Podder V, Westin SN, Corr BR, Coleman RL, Pothuri B, Moore KN, Slomovitz BM. Homologous recombination deficiency in endometrial cancer: shedding light on recent clinical findings. Int J Gynecol Cancer. 2026 02; 36(2):102859.
-
Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N. A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2). Int J Gynecol Cancer. 2026 06; 36(6):102654.
-
Matsuo K, Enserro DM, Wright JD, Roman LD, Powell MA, Miller DS, Nagel CI, Thaker PH, Mannel RS, Stuckey AR, Guntupalli SR, Sukumvanich P, Geller MA, Vargas R, Konecny GE, Warshal DP, Tewari KS, Spirtos NM, Pothuri B, Creasman WT, Mutch DG. Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2025 10; 201:184-194.
-
Wang SM, Dexter J, Wolsky R, Lefkowits C. Management of Advanced Stage Endometrial Cancer With Non-Measurable Disease After Surgery. Curr Treat Options Oncol. 2025 Sep; 26(9):820-828.
-
Corr BR, Thomas SM, Haight PJ, Stock E, Floyd J, Borden LE, Tunnage I, Secord AA, Arend R, Jackson AL, Wright JD, Konecny G, Castellano T, Ko E, Podwika S, Backes F, Spinosa D, Mullen M, Washington C, Pothuri B, Smitherman C, Harsono AAH, Khadraoui H, Suzuki Y, Salani R, Powell K, Subbarao S, Gaillard S. Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability. Gynecol Oncol. 2025 10; 201:69-75.
-
Abu-Rustum NR, Campos SM, Amarnath S, Arend R, Barber E, Bradley K, Brooks R, Chino J, Chon HS, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Gaillard S, Giuntoli R, Glaser S, Howitt BE, Landrum L, Lea J, Lee N, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Nieto K, Nwachukwu C, Podoll M, Rodabaugh K, Salani R, Schorge J, Schuetze S, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian N, Sambandam V. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025. J Natl Compr Canc Netw. 2025 08; 23(8):284-291.
-
Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 09; 200:58-67.
-
Lee SS, Secord AA, Friedman S, Hade EM, Smitherman C, Bisht N, Borden L, Jackson AL, Backes F, Thaker P, Arend R, Wright JD, Corr B, Ko E, Konecny G, Podwika S, Bae-Jump V, Hacker KE, Pothuri B. Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2). Gynecol Oncol. 2025 08; 199:152-158.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|